ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 823,92
0,15%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Navidea Biopharmaceuticals Inc (NAVB)

  7. Navidea Biopharmaceuticals Inc (NAVB) Actualités

NAVB

Navidea Biopharmaceuticals (NAVB)

Navidea Biopharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:AMEX:NAVB
DateHeureSourceTitreSymboleSociété
21/12/202321h32Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:NAVBNavidea Biopharmaceuticals Inc
06/12/202300h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:NAVBNavidea Biopharmaceuticals Inc
01/12/202317h49Edgar (US Regulatory)Form 8-K - Current reportAMEX:NAVBNavidea Biopharmaceuticals Inc
23/10/202319h56Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesAMEX:NAVBNavidea Biopharmaceuticals Inc
06/10/202303h01Business WireNavidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common StockAMEX:NAVBNavidea Biopharmaceuticals Inc
05/10/202322h21Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:NAVBNavidea Biopharmaceuticals Inc
15/09/202321h42Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsAMEX:NAVBNavidea Biopharmaceuticals Inc
11/09/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:NAVBNavidea Biopharmaceuticals Inc
15/08/202323h53Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:NAVBNavidea Biopharmaceuticals Inc
11/08/202322h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:NAVBNavidea Biopharmaceuticals Inc
10/08/202315h29Business WireNavidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing PanelAMEX:NAVBNavidea Biopharmaceuticals Inc
31/07/202315h32Business WireNavidea Biopharmaceuticals, Inc. Presses Ahead, Embraces OpportunitiesAMEX:NAVBNavidea Biopharmaceuticals Inc
29/07/202302h23Business WireNavidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American DeterminationAMEX:NAVBNavidea Biopharmaceuticals Inc
27/07/202323h20Business WireNavidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial OfficerAMEX:NAVBNavidea Biopharmaceuticals Inc
13/07/202323h09Business WireNavidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps DownAMEX:NAVBNavidea Biopharmaceuticals Inc
03/07/202322h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:NAVBNavidea Biopharmaceuticals Inc
30/06/202316h46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:NAVBNavidea Biopharmaceuticals Inc
30/06/202315h16Business WireNavidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain AssetsAMEX:NAVBNavidea Biopharmaceuticals Inc
16/06/202323h23Edgar (US Regulatory)Current Report Filing (8-k)AMEX:NAVBNavidea Biopharmaceuticals Inc
16/06/202323h00Edgar (US Regulatory)Securities Registration (section 12(g)) (8-a12g)AMEX:NAVBNavidea Biopharmaceuticals Inc
16/06/202322h54Business WireNavidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common StockAMEX:NAVBNavidea Biopharmaceuticals Inc
16/06/202319h52Business WireNavidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone PaymentAMEX:NAVBNavidea Biopharmaceuticals Inc
07/06/202322h00Business WireNavidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateAMEX:NAVBNavidea Biopharmaceuticals Inc
02/06/202323h54Business WireNavidea Biopharmaceuticals, Inc. Receives NYSE American NoticeAMEX:NAVBNavidea Biopharmaceuticals Inc
01/06/202323h53Business WireNavidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps DownAMEX:NAVBNavidea Biopharmaceuticals Inc
01/06/202312h03Edgar (US Regulatory)Specialized Disclosure Report (sd)AMEX:NAVBNavidea Biopharmaceuticals Inc
23/05/202300h30Business WireNavidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at MarketAMEX:NAVBNavidea Biopharmaceuticals Inc
11/05/202323h35Business WireNavidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical OfficerAMEX:NAVBNavidea Biopharmaceuticals Inc
11/05/202322h57Edgar (US Regulatory)Quarterly Report (10-q)AMEX:NAVBNavidea Biopharmaceuticals Inc
08/05/202322h12Business WireNavidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for CommunicationsAMEX:NAVBNavidea Biopharmaceuticals Inc
 Showing the most relevant articles for your search:AMEX:NAVB

Dernières Valeurs Consultées

BIT
P110U0
Bnp Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés